Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial Article

Open Access International Collaboration

cited authors

  • Del Prato, Stefano; Li, Zhuoru; Ramasundarahettige, Chinthanie; Branch, Kelley R. H.; Lam, Carolyn S. P.; Lopes, Renato D.; Pratley, Richard; Rosenstock, Julio; Sattar, Naveed; Gerstein, Hertzel C.

Publication Date

  • September 28, 2024

webpage

published in

category

keywords

  • Cardiovascular disease
  • Fibrosis-4 score
  • GLP-1 analogue
  • Randomized trial
  • Type 2 diabetes MAFLD

volume

  • 23

issue

  • 1